Determination of the welfare status of freeroaming dogs in two urban centres in Chile. / Determinación del estado de bienestar en perros callejeros de dos centros urbanos de Chile.

Free-roaming dogs are not only a public health and ethical problem, they are also an environmental and economic one. Although the general belief is that freeroaming dogs are not in good condition, there have been insufficient studies in Chile to address and analyse the issue. The objective of this research was to assess the welfare of free-roaming dogs in the centre of the cities of Santiago and Valparaíso. The evaluation was carried out using an observational method and assessed a total of 554 dogs. The following variables were analysed: body condition, motor impairment, skin condition, respiratory disease, reaction to humans and other variables. In addition, spatial distribution was considered, and age, sex and social behaviour were estimated. When the results were analysed in terms of frequency, it was found that, in Valparaíso (n = 204), 37% of the dogs assessed had compromised welfare (poor or fair), while 63% had positive welfare (good or optimal). In contrast, in Santiago (n = 350), only 21.7% had compromised welfare, while 78.3% had positive welfare. With respect to social behaviour, 55% of the dogs assessed in Valparaíso and 68% of those assessed in Santiago led a solitary lifestyle. Although most of the individuals were in good condition, a high percentage were unable to meet the requirements for them to live in harmony with their environment.

Les chiens de rue ou errants posent des problèmes non seulement de santé publique et d'éthique, mais aussi environnementaux et économiques. La condition générale de ces chiens est intuitivement perçue comme n'étant pas bonne mais au Chili le sujet n'a guère fait l'objet d'analyses approfondies. Les auteurs présentent les résultats d'une étude visant à évaluer le bien-être animal des chiens errants du centre-ville de Santiago et de Valparaíso. Cette évaluation a reposé sur l'observation de 554 chiens au total et sur l'analyse d'un certain nombre de variables dont la condition physique, les difficultés motrices, l'état de la peau et du pelage, la présence de maladies respiratoires et les réactions face à l'être humain. La distribution spatiale des chiens examinés a été consignée, ainsi que l'âge estimé, le sexe et le comportement social de chaque animal. Les résultats ont été analysés en termes de fréquence. À Valparaíso, les observations ont fait état d'un niveau de bien-être compromis (allant de mauvais à médiocre) chez 37 % des chiens (n = 204) et d'un pourcentage de 63 % de chiens présentant un niveau de bien-être satisfaisant (bon à optimal). En revanche, à Santiago (n = 350), 21 % seulement des chiens observés présentaient un état de bien-être compromis tandis que 78,3 % présentaient un état de bien-être satisfaisant. En ce qui concerne le comportement social, 55 % des chiens observés à Valparaíso et 68 % de ceux observés à Santiago avaient un mode de vie solitaire. Si la majorité des chiens se trouvaient en bon état physique, un pourcentage élevé d'entre eux ne parvenaient pas à satisfaire les besoins leur permettant de vivre en équilibre avec leur environnement.

Los perros callejeros constituyen no solo un problema de salud pública y ético, sino también, medioambiental y económico. Si bien se cree que estos perros no se encuentran en buenas condiciones, en Chile los estudios que abordan y analizan este tema son insuficientes. El objetivo de esta investigación fue evaluar el bienestar en perros callejeros en el centro de las ciudades de Santiago y Valparaíso. La evaluación se realizó a través de un método observacional en un total de 554 perros, y se analizaron las siguientes variables: condición corporal, dificultad motora, estado de la piel, enfermedad respiratoria, reacción hacia el humano y otras variables. Además, se consideró la distribución espacial y se estimó la edad, el sexo y la conducta social. Los resultados fueron analizados en términos de frecuencia, y se observó que en Valparaíso (n = 204), el 37% de los perros presentaba un bienestar comprometido (malo - escaso) mientras que el 63% presentaba un bienestar favorable (bueno u óptimo). En cambio, en Santiago (n = 350), sólo un 21,7% presentaba un estado de bienestar comprometido mientras que el 78,3% presentaba un estado de bienestar favorable. Asimismo, respecto a la conducta social, un 55% de los perros evaluados en Valparaíso y un 68% de los evaluados en Santiago mostraron un estilo de vida solitario. Si bien los individuos en su mayoría se encontraban en buenas condiciones, un alto porcentaje no lograba satisfacer las necesidades para estar en equilibrio con su entorno.

L-arginine supplementation normalizes bone turnover and preserves bone mass in streptozotocin-induced diabetic rats.

Osteopenia, an important complication of diabetes mellitus, is responsible of an increase in bone fracture and of a delay in fracture healing. The pathogenesis of this complication is unclear, however decreased availability and synthesis of nitric oxide (NO) may be regarded as a possible cause of disregulation of bone turnover. The aim of our study was to evaluate the effect of streptozotocin (STZ)-induced diabetes in the rat on bone mineral density (BMD) and bone turnover. We also examined whether supplementation of L-arginine (which acts as a NO substrate) could be beneficial for bone. After 6 weeks of STZ treatment, diabetic rats showed a significant decrease of BMD in the whole body, at the spine, at the pelvis, and at the femur. Bone turnover evaluation revealed a significant decrease in the serum levels of osteocalcin (a marker of bone formation), and an increase of the serum levels of the C-terminal telopeptide of type I collagen (RatLaps; a marker of bone resorption). L-arginine supplementation prevented the diabetes-induced reduction of BMD and osteocalcin, and the increase of RatLaps. These pharmacological actions of L-arginine produce a new suggestion that increase of NO synthesis and availability is potentially useful for effective prevention and treatment of osteopenia associated with diabetes.

Experimental study on the toxicity and the local and systemic tolerability of gemcitabine after topical treatment of the rabbit bladder.

This study investigated gemcitabine administered intravesically to establish the local and systemic tolerability necessary for clinical trials. Gemcitabine was directly administered via catheter into the bladders of 24 male New Zealand rabbits weighing an average of 1.9+/-0.08 kg. Three groups received weekly gemcitabine for 5 (50 mg/kg) or 8 (25 mg/kg or controls) weeks. Animals were inspected daily for signs of toxicity and distress, body weight changes, and water and food consumption; electrocardiogram, blood pressure, and urinalysis were recorded before dosing and after 4 and 8 weeks of treatment. The rabbits were euthanized, and a full necropsy was performed on day 1 after the last instillation. Principal organs (spleen, thymus, testis, and muscle) and plasma samples were analyzed for the systemic absorption of gemcitabine. The 25-mg/kg dose was well tolerated with no clinical side effects. At 50 mg/kg, signs of mild myelosuppression and severe symptomatic toxicity (leg weakness, and hair and body weight loss) was evident after 3 weeks of treatment and three of the seven animals in this group died after four doses. Necropsies revealed normal bone marrow cellularity and organ histology at both doses. No significant systemic drug absorption was seen. These findings suggest that intravesical administration of gemcitabine does not produce organ-specific toxicity, but the higher dose (50 mg/kg) may represent the threshold above which increasing morbidity may occur.

[Hemodynamic monitoring using a long radial catheter]. / Monitoraggio emodinamico con catetere radiale lungo.

UNLABELLED: Percutaneous radial artery catheterization for blood gas monitoring and continuous arterial pressure recording has become a common procedure in the management of patient undergoing cardiac surgery operations. Since radial artery pressure does not accurately reflect central aortic pressure, in the immediate post bypass period and in low cardiac output states, specially during catecholamine infusion, a long arterial line is necessary. The author has been using several techniques of central arterial cannulation from 1980 to 2002 in 6303 procedures using central radial artery, including 734 patients with Length of Stay (LOS) >96 h, and 1880 patients with Seldinger Technique, using polyurethane Arrow catheter 16 G 50 cm. The use of long radial catheter has been recently associated, for the control pulse analysis, with Picco technology successfully in 74 patients undergoing cardiac and vascular surgery operations, having no complication. The author referred on the clinical aspect connected with the use of central radial catheter with special emphasis on safety of the procedure. a) Large retrospective review on the use of long arterial catheter (6303), including prospective (50 patients) Trial of consecutive unrandomized patients. b) SETTING: Cardiac surgery end vascular department in a large over 1000 beds and 4 Hospitals Administration (the study has been limited to cardiac surgery unit).

[Long-term therapy of benign prostatic hyperplasia. Our experience]. / Terapia a lungo termine dell'ipertrofia prostatica benigna. La nostra esperienza.

BACKGROUND: In order to evaluate the benefit of long-term medical treatment (4 years) in benign prostatic hyperplasia in June 1992 we prospectively started a not randomized study in selected benign prostatic hyperplasia patients for whom surgery was not indicated because of high surgical or post-surgical risk, or when they refused the intervention. METHODS: We included in the study 239 outpatients; 118 of them were affected by concomitant cardiovascular illness, 37 by neurologic diseases, 29 by neoplastic diseases and 55 refused surgery for the possible general or specific complications like retrograde ejaculation. All subjects have been checked every six months by transabdominal ultrasonography of the urinary tract, evaluation of the prostate volume and percent of post-micturitional residue, associated with uroflussometry. The patients have been divided into three groups and treated by finasteride, mepartricin, alfuzosin, doxazosin. The enlistment concluded in December 1995 and the follow-up extended up to December 1999. RESULTS: Our data clinically and statistically allow to confirm the validity of drug therapy for benign prostatic hyperplasia, not only in selected patients with high surgical risk, but also in subjects without a significant morbidity. CONCLUSIONS: In these patients, drug therapy may resolve the pathology, or allow the use of minimally invasive surgery (i.e. lasertherapy, transuretheral incision, etc.).

Role of soy diet and L-arginine in cyclosporin-A-induced osteopenia in rats.

Our previous studies show that chronic administration of L-arginine decreases cyclosporin-A-induced bone loss. The present study was designed to investigate whether a soy diet could prevent cyclosporin A-induced osteopenia and eventually improve the protective effect of L-arginine. Rats on soy diet were treated with cyclosporin-A, L-arginine, cyclosporin-A + L-arginine or saline. Control groups received a normal diet and the same pharmacological treatment. Our results show that a soy diet prevents osteopenia only in the spinal cord (+30%) and confirm the protective effect of L-arginine in cyclosporin-A-induced osteopenia in whole body, pelvis and spine of rats on a normal diet (+31%, +55%, +55%, respectively). Moreover these data show that the osteoprotective effect of L-arginine in the whole body, pelvis and spine improves in the case of soy diet (+60%, +72%, +89%, respectively). The results suggest that a soy diet exerts a positive effect in cyclosporin-A-induced osteopenia only in sites with high turn-over and improves the osteoprotective effect of L-arginine.

L-arginine prevents bone loss and bone collagen breakdown in cyclosporin A-treated rats.

Cyclosporin A is implicated in the pathogenesis of post-transplantation bone disease. Because of recent evidence that cyclosporin A may cause renal and cardiovascular toxicity by inhibiting nitric oxide (NO) activity, and that NO slows bone remodeling and bone loss in animal and human studies, we investigated a possible link between NO production and beneficial effects on bone health in cyclosporin A-treated rats. Thirty-six 10-week-old male rats were assigned to six groups of six animals each, and treated for 4 weeks with: vehicle; cyclosporin A; L-arginine; N(G)-nitro-L-arginine methylester (L-NAME, a general inhibitor of NO synthase activity); a combination of cyclosporin A+L-arginine; and a combination of cyclosporin A+L-NAME. Whole body and regional (spine and pelvis) bone mineral content of rats were measured under basal conditions and at the end of the treatment period by dual-energy X-ray absorptiometry (DXA) scanning. Femur weights and serum concentrations of pyridinoline, a reliable marker of bone resorption, were measured at the end of the study period. Cyclosporin A-, L-NAME-, and cyclosporin A+L-NAME-treated rats had significantly lower bone mineral content and femur weights, and significantly higher pyridinoline levels than did control animals. The administration of L-arginine appeared to prevent bone loss caused by cyclosporin A, suggesting that this amino acid, which can be converted to produce NO, might prove useful in preventing disturbed bone modeling and inhibition of bone growth associated with cyclosporin A therapy.

Adrenomedullin and ocular inflammation in the rabbit.

Adrenomedullin administered peripherally in the rabbit (at doses of 1.25, 2.5 and 5 microg/kg ) caused a dose-dependent conjunctival hyperemia accompanied by an increase of inflammatory cell number and prostaglandin E(2) concentration in the aqueous humor, and of uveal vascular response and myeloperoxidase activity. The inflammatory effect of the peptide, injected at the dose of 5 microg/kg, was abolished by pretreatment with the inhibitor of nitric oxide synthase, N(G)-nitro-L-arginine methylester (50 mg/kg, i.v.). Moreover, the i.v. pretreatment with the calcitonin gene-related peptide 8-37 fragment (calcitonin gene-related peptide, CGRP-(8-37), 2.5 microg/kg), receptor antagonist of CGRP, did not inhibit the conjunctival hyperemia. In contrast, the i.v. pretreatment with the adrenomedullin receptor antagonist, adrenomedullin-(22-52) fragment (2.5 microg/kg), abolished adrenomedullin-induced ocular inflammation. These results suggest that adrenomedullin causes conjunctival hyperemia, and this effect involves the nitric oxide system acting through specific adrenomedullin receptors.

Contribution of proanthocyanidins to the peroxy radical scavenging capacity of some Italian red wines.

Highly reactive radicals, ROO(*), were generated from 2, 2'-azobis[2-(2-imidazolin-2-yl)propane] and linoleic acid. The ROO(*) scavenging capacity of some Italian red wines was evaluated following the changes in oxygen consumption. Under the experimental conditions the time course of oxygen consumption shows two typical behaviors: trolox-like (class I) and gallic acid-like (class II). Usually the time course of wine was similar to that of gallic acid. The rate of oxygen consumption was found to decrease exponentially with the amount of wine or gallic acid added to the test solution. On this basis the capacity of red wines to scavenge peroxy radicals was expressed as content of gallic acid (S(GA)). The S(GA) values were found to be correlated to the amount of total proanthocyanidins and total polyphenols of some Italian red wines (p < 0.01). The proanthocyanidins extracted from seeds were shown to make a major contribution to the peroxy radical scavenging capacity of red wines, whereas, interestingly, the chemical class of the low molecular weight tannins reactive to vanillin did not correlate with the S(GA) values.

Effect of acetyl-L-carnitine on ethanol consumption and alcohol abstinence syndrome in rats.

The effect of acetyl-L-carnitine on alcohol consumption and its possible ability to alleviate all symptomatology of ethanol withdrawal syndrome has been investigated in rats. Alcohol-dependence was induced in animals (9-15 g/kg ethanol solution at 20% for a period of 4 days) in order to measure the effects of acetyl-L-carnitine on ethanol abstinence syndrome. The ethanol dependence phase was characterized by the onset of signs and responses of progressive severity: hyperactivity, tremors, spastic rigidity and spontaneous convulsive seizures. After 4 days, 8 h after the last ethanol administration, two groups of animals received acetyl-L-carnitine (125 mg/kg and 250 mg/kg intraperitoneally, respectively) and the intensity of the withdrawal syndrome was assessed on the basis of the appearance of tremors. The effect of acetyl-L-carnitine on voluntary alcohol consumption was investigated in a rat line selected for innate ethanol preference. For 15 days the animals could freely choose both water and/or a hydroalcoholic solution (10% p:v). Acetyl-L-carnitine was given intraperitoneally at a dose of 200 mg/kg twice daily. The water and the hydroalcoholic solution levels were checked at the same time daily. Acetyl-L-carnitine treatment significantly reduced the onset of tremors in ethanol withdrawal syndrome as well as the level of ethanol intake in alcohol-preferring rats. These results suggest a possible pharmacological role of acetyl-L-carnitine in the treatment of alcohol dependence.

Antiinflammatory activity of adrenomedullin in the acetic acid peritonitis in rats.

The antiinflammatory effect of ADM was studied in different models of inflammation and compared to the one of CGRP. Peptides were active against acetic acid-induced peritonitis in the rats. ADM and CGRP exerted the antiinflammatory effect at different doses, 400 and 20 ng/kg respectively, but with different efficacy (ADM >CGRP). This effect was blocked by pretreatment with CGRP (8-37) fragment or with L-NAME. No antiinflammatory activity was evidenced against serotonin- or carrageenin-induced rat paw edema. Our data suggest that ADM exerts antiinflammatory activity in the model characterized by a vascular component. This effect involves CGRP receptors and appears to be mediated by nitric oxide system.

Effects of centrally injected amylin on sexually behavior of male rats.

Amylin (AMY) is a peptide of pancreatic origin principally involved in the carbohydrate metabolism, but that may interfere with central and peripheral dopamine (DA) pathways. The peptide, injected intracerebroventricularly (ICV) at the dose of 2.5 microg/rat, induced a decrease of copulatory activity in good copulators (GCO) and sluggish (SLU) male rats. The dose of 0.1 microg/rat did not affect significantly the sexual behavior of GCO rats, whereas AMY 0.5 microg/rat increased only the latency and reduced the frequency of ejaculation. At the dose of 2.5 microg/rat AMY antagonized the activation of sexual behavior induced by the DA receptor agonist, apomorphine administered subcutaneously (SC) at the dose of 100 microg/kg. Moreover, this inhibitory effect was blocked by the calcitonin gene-related peptide and AMY receptor antagonist, CGRP (8-37) fragment (injected ICV at the dose of 1 microg/rat). These data suggest that AMY may exert inhibitory effects on male sexual behavior in rats, probably interfering with central DA neurotransmission and with CGRP receptors.

Effects of centrally of peripherally injected adrenomedullin on reserpine-induced gastric lesions.

Adrenomedullin intracerebroventricularly administered (0.1 to 20 ng/rat i.c.v.), showed significant gastroprotective activity in a dose-dependent manner. When the peptide was intravenously administered (1 to 1000 ng/kg i.v.) it did not show significant gastroprotective activity in the same test. The gastroprotective effect of the peptide (10 ng/rat) was abolished by bilateral adrenalectomy, by pretreatment with the beta-adrenoceptor antagonist, propranolol (1 mg/kg i.p.), or by a calcitonin gene-related peptide (CGRP) receptor antagonist, CGRP-(8-37) fragment (1 or 10 ng/rat i.c.v.). This study showed that adrenomedullin is protective against reserpine-induced gastric lesions, that the action involves sympathetic nerve activity, and moreover interferes with CGRP receptors.

Involvement of DA1 and DA2 receptors in the gastroprotective activity of amylin in the rat.

Peripheral administration of amylin (40 microg kg-1) exerts gastroprotective effects in the reserpine-induced gastric lesions in the rat. This activity is decreased by pretreatment (30 min before) with (-)-sulpiride (0.1 mg kg-1 s.c.) or domperidone (0.1-2.5 mg kg-1 per os), dopamine DA2 antagonists. Pretreatment with SCH 23390 (0.5-4 mg kg-1 s.c.), a DA1 antagonist, at the maximal dose used, also significantly decreased the gastroprotective activity of the peptide. Amylin does not exert any gastroprotective effect in indomethacin-pretreated rats (7.5 mg kg-1 s.c., 30 min before), as well as in the aspirin-induced ulcer test (200 mg kg-1 per os at the time of amylin administration). Our data confirm that the gastroprotective effect of amylin in reserpine-induced gastric lesions involves, at least in part, the dopaminergic transmission, interfering with both the DA1 and DA2 receptor subtypes.

Effect of amylin in various experimental models of gastric ulcer.

Subcutaneous administration of amylin (20-40 micrograms/kg) prevented, in a dose-dependent manner, reserpine- and serotonin-induced gastric damage, but the anti-ulcer effect was not present when lesions were induced by pylorus ligation. The protective effect of amylin was inhibited by pretreatment with capsicin as well as CGRP-(8-37), a calcitonin gene-related peptide (CGRP) and amylin receptor antagonist, and was significantly reduced by domperidone, a dopamine D2 receptor antagonist, or neostigmine, an inhibitor of acetylcholinesterase. Our data suggest that the gastroprotective activity of amylin in some experimental models of gastric ulcers involves capsaicin-sensitive fibers and CGRP receptors. Moreover, the peptide interferes, at least in part, with the dopaminergic and parasympathetic systems.

[Measurement of cardiac output with continuous thermodilution. b1 Clinical experience with the Intellicath-Vigilans system]. / Gittata cardiaca misurata mediante termodiluizione continua. Esperienza clinica con il sistema Intellicath-Vigilans.

BACKGROUND: Thermodilution cardiac output measurements are commonly obtained by a manual bolus technique with a pulmonary artery catheter. METHODS: A new thermodilution catheter has been developed which utilizes an integral thermal filament and provides semicontinuous online cardiac output. The response of this new device in 25 patients undergoing coronary artery bypass grafting was examined. A total of 250 data pairs was obtained; the cardiac outputs ranged from 2.2 to 11.9 lts.min. RESULTS: The linear regression is represented by the following equation: continuous thermodilution = 0.7196 bolus thermodilution +1.038. The correlation coefficient was 0.75; the mean bias was 0.493 +/- 1.034. CONCLUSIONS: The new technique provides acceptable accuracy in many clinical situations except when sudden haemodynamic changes occur.

[Propofol in coronary diseases. Haemodynamic evaluation of some anesthetic regimes]. / Il propofol nel coronaropatico. Valutazione emodinamica di vari regimi anestetici.

The haemodynamic effect of two regimens of propofol-fentanyl anaesthesia versus a standard isoflurane-fentanyl anaesthesia were compared perioperatively in 30 patients with good left ventricular function undergoing coronary artery bypass grafting. Anaesthesia was induced in all patients with fentanyl 14 micrograms/kg, pancuronium 0.1 mg/kg, and thiopental 1 mg/kg. Anaesthesia was maintained: in 10 patients with a constant propofol infusion of 200 micrograms/kg/min during the pre-bypass period and fentanyl boluses of 1 mg when required (PH Group); in 10 patients with a variable propofol infusion (from 43.09 to 22.42 micrograms/kg/min) during the pre-bypass period and a fixed infusion of 10.47 micrograms/kg/min during the post-bypass period (PL group) in 10 patients with a 1% isoflurane administration throughout the intraoperative period (F Group). The analgesia in the PL and F Groups was obtained with a fentanyl infusion of 0.3 microgram/kg/min during the prebypass period, 0.11 microgram/kg/min during the postbypass period. PL Group patients received 0.06 microgram/kg/min of fentanyl during the first three hours of the intensive care unit (TI) stay. The PL Group showed a significant better haemodynamic control of oxygen consumption indexes; PH Group patients had a major myocardial depression, routinely requiring the use of cardiokinetic agents in the post-bypass period. Intraoperative opioid consumption was similar in all Groups whereas the F Group showed a significantly higher fentanyl requirement during the TI period.

Amylin given by central or peripheral routes decreases gastric emptying and intestinal transit in the rat.

The effect of rat amylin on gastric emptying and intestinal transit in the rat was examined. Amylin administered intracerebroventricularly (1, 2, 2.5 or 4 micrograms/rat) produced the maximal decrease in gastric emptying and intestinal transit at the dose of 2.5 micrograms/rat. Higher doses produced a lower effect. Peripheral administration (25, 50 or 100 micrograms/kg) produced dose-dependent effects. Pre-treatment with neostigmine blocked the effect of amylin when it was centrally injected, while the effect of amylin given peripherally was partially reduced. Pre-treatment with domperidone decreased the inhibitory effect of peripherally injected amylin, but no effect was observed when the peptide was centrally injected.

Behavioral effects of amylin injected intracerebroventricularly in the rat.

Amylin is a peptide of pancreatic origin that has been reported to possess high-affinity binding sites in the brain and to affect central dopaminergic and serotonergic neurotransmission. Administered ICV the peptide induced a dose-dependent decrease of locomotor activity without affecting grooming and sniffing. At a dose of 5 micrograms/ rat, it antagonized the hypermotility and stereotypies induced by s.c. injection of amphetamine (2 mg/kg) or of the dopamine receptor agonist, apomorphine (250 mg/kg). Amylin did not change significantly the effect of haloperidol (0.5 mg/kg, s.c.) on locomotor activity, grooming, and sniffing. Moreover, the peptide did not modify the locomotor behavior of animals injected with the 5-HT2 antagonist, ritanserin (2 mg/kg, s.c.). These results suggest that amylin may exert motor effects, probably by interfering with central dopaminergic neurotransmission.